Four peptide categories, one quality standard.
Each Ceretropic Labs research area is defined by a specific scientific target and a specific supply gap. We prioritise compounds where the underlying biology is well-characterised but the supply-side execution has been inconsistent.
Regenerative peptides
Copper-peptide complexes and tissue-signaling compounds that modulate extracellular matrix synthesis, wound healing pathways, and hair follicle activity. The category traces back to Loren Pickart's original work on GHK isolation in the 1970s, with sustained research output through the 1990s on copper-complex formulations.
First launch: GHK-Cu
GHK-Cu (glycyl-histidyl-lysine copper complex) activates over 4,000 genes involved in skin repair, collagen synthesis, and antioxidant response. The compound sits in a well-documented research space with decades of peer-reviewed data. What has been missing from the research peptide market is consistent copper-complex stability across batches.
| Compound | GHK-Cu (Cu(II) peptide complex) |
| Molecular weight | 402.84 g/mol |
| Purity standard | ≥ 99% (HPLC) |
| Formulation | Phosphate buffered, pH 6.5 |
| Distribution | ghkcu.rs (Serbian market) |
| Status | Shipping Q4 2026 |
Metabolic peptides
GLP-1 receptor agonists and related incretin-pathway compounds. The category covers the most clinically validated weight-management and glucose-regulation research tools of the past decade.
Compounds in development
- Retatrutide — Triple agonist (GLP-1/GIP/glucagon). Phase 3 data shows the strongest body composition signal of any compound in class
- Tirzepatide — Dual GIP/GLP-1 agonist. Reference standard for metabolic research
- Semaglutide — Pure GLP-1 agonist. Longest post-approval safety record
- Cagrilintide — Amylin analog. Studied in combination with semaglutide (CagriSema) for compounded appetite regulation
Target launch: Q1 2027, through regional distribution partners with cold-chain capability.
Longevity peptides
Compounds with research signal on cellular aging mechanisms. The category pulls from mitochondrial-derived peptides, telomere maintenance research, and senolytic development.
Compounds in development
- MOTS-c — Mitochondrial-derived peptide, AMPK pathway activation. Metabolic and exercise-adaptation research
- Epithalon — Tetrapeptide from Khavinson's work on pineal and telomerase regulation
- SS-31 (Elamipretide) — Cardiolipin-binding peptide, cardioprotection and age-related muscle research
- Humanin — Mitochondrial-encoded cytoprotective peptide
Target launch: Q2 2027.
Healing & recovery peptides
Tissue repair compounds with strong preclinical signal across tendon, ligament, gut mucosa, and vascular models. The category is defined by two anchor compounds and a growing set of derivatives.
Compounds in development
- BPC-157 — Pentadecapeptide from gastric juice protein. Angiogenesis, tendon healing, gut barrier research
- TB-500 (Thymosin Beta-4) — Actin-sequestering peptide, cell migration and tissue repair models
- KPV — Anti-inflammatory tripeptide from alpha-MSH C-terminus
- GHK-Cu + BPC + TB stack — Combined formulation under formulation research
Target launch: Q2 2027.